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Introduction: Pseudoxanthoma elasticum (PXE) is a rare disease caused by mutations 
in the ABCC6 gene. Vitamin K1 is involved in the posttranslational carboxylation of some 
proteins related to inhibition of the calcification process. Our aim was to investigate, 
in patients affected by PXE, baseline levels of vitamin K1-dependent proteins and 
-metabolites and whether parenteral administration of phytomenadione was effective in 
modulating their levels.
Methods: We included eight PXE patients with typical clinical symptoms (skin, retina, 
and vascular calcification) and two ABCC6 causative mutations; 13 clinically unaffected 
first-degree patients’ relatives (9 carrying one ABCC6 mutation and 4 non-carriers). 
We assessed urinary vitamin K1 metabolites and serum Glu- and Gla-OC, Gas6 and 
undercaboxylated prothrombin (PIVKA-II), at baseline and after 1 and 6 weeks after a 
single intramuscular injection of 10 mg vitamin K1.
Results: Comparison of PXE patients, heterozygous, and non-carriers revealed dif-
ferences in baseline levels of serum MK-4 and of urinary vitamin K metabolites. The 
response to phytomenadione administration on vitamin K-dependent proteins was 
similar in all groups.
Conclusion: The physiological axis between vitamin K1 and vitamin K-dependent pro-
teins is preserved; however, differences in the concentration of vitamin K metabolites and 
of MK-4 suggest that vitamin K1 metabolism/catabolism could be altered in PXE patients.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE) is a rare disease caused by mutations in the ABCC6 gene encod-
ing for the multidrug resistance-associated protein 6 (MRP6) highly expressed in the liver (1). The 
disease is characterized by progressive calcification of elastic fibers that undergo fragmentation and 
deformation with loss of function. Retinal damage at Bruch’s membrane causing central blindness, 
TABLE 1 | Baseline characteristics of pseudoxanthoma elasticum (PXE) patients, 
ABCC6 mutation carriers, and non-carriers.
PXE patients 
(n = 8)
ABCC6 carriers 
(n = 9)
Non-carriers 
(n = 4)
Age (years) 39 ± 13 48 ± 17 57 ± 5
Sex (women) 6 (75%) 5 (55%) 1 (25%)
Weight (kg) 72 ± 11 65 ± 10 74 ± 4
BMI (kg/m2) 29 ± 5.1 25 ± 3 28 ± 4
Smoking
Current 2 (25%) 4 (44%) 1 (25%)
Past 1 (12%)
Alcohol 1 (12%) 2 (22%) 1 (25%)
Dyslipidaemia 2 (25%) 3 (33%) 1 (25%)
Systolic blood  
pressure (mmHg)
117 ± 12 110 ± 20 133 ± 10
Diastolic blood  
pressure (mmHg)
71 ± 18 68 ± 14 87 ± 8
Ankle–brachial index 1.12 ± 0.2 1.14 ± 0.08 1.25 ± 0.1
<0.9 1 (12%) 0 0
>1.4 2 (25%) 1 (10%) 1 (25%)
Data are shown as mean ± SD or number (percentage).
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skin papules, and folds as well as vascular calcification respon-
sible for ischemia are the most frequent clinical features (2).
The disease pathogenesis has not yet completely understood, 
though several hypotheses have been postulated. A series 
of in  vitro and in  vivo studies suggested that absent or non-
functional MRP6 can influence the availability of circulating 
factors from the liver, which are physiologically required to 
prevent aberrant calcification and which are able to modulate 
the phenotype of mesenchymal cells, such as fibroblasts (3). 
As a consequence of fibroblasts’ abnormal protein profile (4), 
extracellular matrix components are differentially synthesized 
and/or degraded thus altering connective tissue homeostasis 
(4–6). Within this context, progressive mineralization of elastic 
fibers is probably sustained by an altered balance between fac-
tors inducing and inhibiting the mineralization process, such as 
fetuin A, Matrix Gla Protein (MGP), alkaline phosphatase, and 
pyrophosphate (7–11).
The association of vitamin K deficiency with ectopic cal-
cification and with PXE-like phenotype (12, 13) has recently 
drawn attention to a number of proteins involved in ectopic 
calcification. Some of these proteins, such as MGP, osteocalcin 
(OC) and growth arrest-specific protein 6 (Gas6), require 
posttranslational vitamin K-dependent carboxylation to be 
fully active. The carboxylase enzyme uses the oxygenation of 
vitamin K hydroquinone to subtract a hydrogen from glutamyl 
residues (Glu) and to generate a carbanion that, incorporating 
CO2 by nucleophilic attack, produces a carboxylated-Glu known 
as Gla (14).
The observations that: (i) MGP levels were decreased in 
the serum of PXE patients compared to non-carriers (15), 
(ii) the concentration of MGP in the serum of Abcc6−/− mice 
was similarly reduced when compared to wild-type animals 
and (iii) most of the MGP isolated from the liver of Abcc6−/− 
mice was largely under-carboxylated, thus exhibiting reduced 
or no activity (16), suggested a possible pathogenic role of 
vitamin K in PXE (17). Consistently, serum vitamin K con-
centrations in PXE patients appeared significantly decreased 
compared to control subjects (18). Despite these findings, 
treatment of Abcc6−/− mice with different forms of vitamin K 
failed to counteract the calcification process (19–21). In addi-
tion, in vitro experiments on fibroblasts isolated from controls 
and PXE patients demonstrated that these cells had a similar 
dose-dependent uptake of both vitamin K1 and K2 and had a 
significant increase of total protein carboxylation. By contrast, 
Gla-MGP was significantly lower in PXE fibroblasts (9), 
indicating that, in these patients, MGP cannot be efficiently 
carboxylated by fibroblasts, even in the presence of an adequate 
amount of the vitamin.
It remains questionable whether vitamin K metabolism is 
altered in PXE patients, since type and dosage of vitamin K have 
different effects depending on the model being studied (22, 23).
Therefore, we measured, for the first time in PXE patients 
and in unaffected subjects (i.e., heterozygous ABCC6 muta-
tion carriers and non-carriers), baseline levels of vitamin 
K-dependent proteins and -metabolites and their changes after 
parenteral administration of a single dose of phytomenadione 
(vitamin K1).
PATIENTS AND METHODS
Pseudoxanthoma elasticum patients and unaffected individu-
als (patients’ first-degree relatives) were recruited through the 
Spanish Association of PXE Patients. Inclusion criteria for 
patients were: typical clinical features (i.e., skin and ocular 
involvement), skin biopsy positive to the von Kossa staining, 
presence of two ABCC6 causative mutations, either homozy-
gous or compound heterozygous (24). Inclusion criteria for 
carriers were: complete absence of PXE clinical symptoms and 
one ABCC6 mutation. Inclusion criteria for non-carriers were: 
absence of PXE clinical manifestations and no ABCC6 muta-
tions. In all cases, exclusion criteria were: negative informed 
consent, lack of molecular diagnosis, vegetarian diet, use of 
warfarin, intention to become pregnant during the study, age 
<18 years and hypersensitivity to vitamin K. Finally, eight PXE 
patients, nine heterozygous carriers, and four non-carriers were 
included in the study. All enrolled subjects were advised to keep 
to their usual diet for the duration of the study.
All participants in the study signed informed consent and the 
research was approved by the Ethical Review and Investigative 
Board of Hospital Universitario Virgen de la Victoria, Málaga, 
Spain.
Genetic analyses were carried out as previously described 
(25, 26).
EDTA, citrated and heparinized plasma, serum and urine 
samples were obtained at baseline and at 1 and 6 weeks after 
a single intramuscular injection in the buttock of 10 mg phy-
tomenadione in 1 ml (Konakion©, Roche Pahrma, Madrid). 
Because subjects had similar body-mass index (Table  1), the 
same dose of 10 mg of phytomenadione was used for all subjects. 
Samples’ collection time points were selected in order to deter-
mine whether treatment has an effect on vitamin K-dependent 
proteins and if these effects are lasting. Effects of treatment may 
in fact be prolonged since vitamin K is extensively recycled 
TABLE 2 | Clinical and molecular features in pseudoxanthoma elasticum (PXE) patients.
Cases Age Mutations Clinical manifestations Phenodex  
Score
Other  
manifestations
Skin (S) Eye (E) Vascular (V) Gastrointestinal (G) Cardiac (C)
PXE 1 27 R1114C
Q378X
Papules Angioid streaks None None None Total score 3
S1/E2/V0/G0/C0
None
PXE 2 27 Del 23–29
Y62H
Laxity Angioid streaks None bleeding None Total score 6
S3/E2/V0/G1/C0
None
PXE 3 33 Del 23–29
Y62H
Laxity Angioid streaks None None None Total score 5
S3/E2/G0/V0/C0
None
PXE 4 33 R1141X
R1141X
Laxity Angioid streaks None None None Total score 5
S3/E2/V0/G0/C0
None
PXE 5 33 R1114C
Q378X
Papules Angioid streaks None None None Total score 3
S1/E2/V0/G0/C0
PXE 6 43 R1141X
R1141X
Laxity Scarring Intermittent 
claudication
None Stroke Total score 10
S3/E3/V2/G0/C2
Hypertension,  
kidney stones
PXE 7 57 R1114C
Q378X
Laxity Scarring None None None Total score 6
S3/E3/V0/G0/C0
Kidney stones
PXE 8 59 R600H
R1314Q
Papules Scarring None Bleeding None Total score 5
S1/E3/V0/G1/C0
Hypertension,  
kidney stones
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prior to elimination, and supplementation is actually provided 
to individuals with normal nutritional intake and in the absence 
of any clinically relevant deficit of the vitamin (27).
Serum menaquinone-4 (MK-4) was measured by reversed-
phase HPLC with fluorimetric detection (Waters 515). 
Chromatography was performed in isocratic conditions using 
an end-capped C18 column. Sample preparation was developed 
according to the protocol previously described (28).
Commercial ELISA kits were used to measure des-γ-carboxy 
prothrombin (DCP) (Prothrombin Induced by Vitamin K Absence 
or Antagonist II—PIVKA-II) in citrated plasma (Asserachrom, 
Diagnostica Stago, Asnière-sur-Seine, France), Fetuin A in 
EDTA-plasma (Quantikine, R&D System Inc., Abingdon, UK), 
Gas6 in serum (USCN, Life Science Inc., Houston, TX, USA), 
under-carboxylated (Glu) OC (EIA, Glu-Oc) in serum (Takara 
Bio Inc., Shiga, Japan), carboxylated (Gla) OC (EIA, Gla-OC) in 
heparinized plasma (Takara Bio Inc., Shiga, Japan).
Urinary 2-methyl-3-(5′-carboxy-3′-methyl-2′-pentenyl)-
1,4-naphthoquinone (7C-aglycone) and 2-methyl-3-(3′-3′-
carboxymethylpropyl)-1,4-naphthoquinone (5C-aglycone) 
meta bolite derivatives of vitamin K were measured at each time 
point by HPLC with electromechanical detection, as previously 
described (29, 30). Urinary vitamin K metabolite concentrations 
were corrected for urinary creatinine concentration.
Statistical analyses were performed using “R: A Language and 
Environment for Statistical Computing.” Comparison between 
groups was performed using a linear mixed-model with PXE as 
fixed effect, adjusted by age and gender and the individual as a 
random effect along the repeated measurements.
RESULTS
Age, gender, and relevant clinical data are detailed for PXE patients, 
heterozygous carriers and non-carriers (Table 1). Standard labo-
ratory parameters (hematology, coagulation parameters, glucose 
and lipid status, mineral and electrolytes, liver, kidney, and thyroid 
function) were similar in all subjects and vitamin K1 treatment 
did not significantly affect any of these parameters (data not 
shown).
Clinical manifestations of PXE involving skin, eyes, the 
vascular system, and other organs were described and quanti-
fied according to the Phenodex Score system (31). PXE patients 
with typical clinical manifestations always gave a total score ≥3 
(Table 2). As expected, to all heterozygous carriers was attributed 
a 0 score since dermal, ocular, vascular, gastrointestinal, and 
cardiac symptoms were not observed (Table 3).
Table  4 show that MK-4 was higher in PXE patients at 
baseline compared to heterozygous and non-carriers. At 1 week 
post-vitamin K1 administration, MK-4 increased in all groups. 
Similar values were also observed at 6 weeks. Statistical analyses 
over repeated measurements indicate that, despite the similar 
behavior observed after treatment, differences between groups 
were maintained over the six week-period of the study (p < 0.05).
The concentrations of the 5C- and 7C-aglycone vitamin K 
metabolites were measured at baseline and after treatment, since 
their levels reflect total vitamin K status. Urinary volume excre-
tion did not reveal significant differences between subjects 
(data not shown). As shown in Table 4, vitamin K1 was largely 
metabolized to terminal 5C-aglycone in all groups. Interestingly, 
5C-aglycone levels in PXE patients and ABCC6 mutation carriers 
were significantly lower than those in non-carriers (p < 0.05). 
A similar trend was observed also as far as 7C-aglycone. To be 
noted that differences between groups were evident already at 
baseline. Figure 1 (lower panels) shows the percentage of 5C- or 
7C-aglycone on total aglycones (5C +  7C) measured in non-
carriers, ABCC6 carriers and PXE patients. These values allow 
to compare, within each group, how vitamin K1 was metabolized 
with time. In particular, in both non-carries and ABCC6 carriers, 
7C-aglycone levels progressively increased over time, whereas an 
opposite trend was observed in PXE patients.
TABLE 3 | Clinical and molecular features in ABCC6 mutation carriers.
Cases Age Mutations Clinical manifestations Phenodex Score Other 
manifestations
Skin (S) Eye (E) Vascular (V) Gastrointestinal (G) Cardiac (C)
C 1 23 R1314Q
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 None
C 2 25 R1141X
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 None
C 3 34 R1141X
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 Hypertension,  
kidney stones
C 4 51 R600H
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 None
C 5 52 R807Q
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 Kidney stones
C 6 63 R600H
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 None
C 7 65 R1141X
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 None
C 8 67 R1141X
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 Kidney stones
C 9 68 R1141X
–
None None None None None Total Score 0 S0/E0/V0/G0/C0 Atrial fibrillation
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In order to investigate the effects of vitamin K1 supplemen-
tation, several vitamin K-dependent proteins were measured. 
Table 4 shows that PIVKA-II concentration were similar in PXE 
patients, in non-carriers and in ABCC6 carriers, at both baseline 
and post-vitamin K administration.
Serum Gas6 protein was similarly expressed at baseline in all 
groups (Table 4). Vitamin K1 administration diminished Gas6 
concentration in all groups. Statistical analyses over repeated 
measurements revealed significant differences after treatment 
compared to baseline.
Figure 2 shows the effect of phytomenadione supplementa-
tion on the carboxylation status of OC, an extra-hepatic vita-
min K-dependent protein involved in the calcification process. 
At baseline, both under-carboxylated (Glu)- and carboxylated 
(Gla)-OC were similar in all groups (data not shown). At 1 
week post-treatment, the ratio between Glu- and Gla-OC was 
significantly reduced in all groups (p <  0.001). At 6 weeks 
after treatment, values returned to baseline concentrations 
(Figure 2).
Finally, as shown in Table 4, fetuin A levels, as expected for a 
non-vitamin K-dependent protein, did not change significantly 
over time.
DISCUSSION
It is well known that vitamin K has a role in the occurrence of 
ectopic calcification (32). Although suboptimal vitamin K status 
has been observed in PXE patients, thus suggesting that this 
vitamin could exert a key role in the defective carboxylation of 
MGP (8, 15, 16, 18); however, other experimental evidence does 
not support this hypothesis [10, 19, 21]. Nevertheless, it remains 
uncertain whether vitamin K metabolism/catabolism is altered 
in PXE patients.
The increased serum MK-4 concentration detected after 
phytomenadione administration indicates that the conversion of 
vitamin K1 to MK-4 is preserved in PXE, confirming previous 
in vitro data (9). However, differences at baseline and after treat-
ment between patients and unaffected individuals may suggest 
possible altered regulation of metabolite production and/or in 
excretion pathways.
The significance of urinary aglycones measurements, as bio-
markers of vitamin K status, resides in the observation that these 
metabolites reflect the excretion of total vitamins K, including 
MK-4 formed by conversion of vitamin K1 (29). In all subjects 
the excretion of the 5C-aglycone was greater than that of 
7C-aglicone. However, at baseline, PXE patients exhibited redu-
ced excretion of the urinary 5C-aglycone, indicating a suboptimal 
vitamin K status (18). Moreover, after vitamin K1 supplementa-
tion, non-carriers and ABCC6 carriers showed an increase of 
urinary 7C—aglycone excretion, whereas an opposite trend was 
present in PXE patients. Although the significance of these data 
could be explored also in the light of biliary excretion pathways 
(29), data suggest that vitamin K metabolism is modified 
in PXE.
To further investigate the effects of parenteral vitamin K1 sup-
plementation, we measured the abundance of DCP, also known 
as prothrombin induced by vitamin K absence (PIVKA-II), an 
abnormal prothrombin molecule with diminished coagula-
tion activity as a consequence of incomplete hepatic vitamin 
K-dependent carboxylation (33, 34). In this study, DCP levels, as 
well as coagulation test parameters, were similar in PXE patients 
and in heterozygous carriers and in non-carriers, confirming 
that vitamin K-dependent coagulation factors are not affected in 
PXE. By contrast, PXE-like manifestations due to mutations in 
the gamma-glutamyl carboxylase gene are associated to altered 
carboxylation of coagulations factors (18).
TABLE 4 | Vitamin K metabolites and dependent proteins at baseline and at 1 and 6 weeks post-phytomenadione administration in pseudoxanthoma elasticum (PXE) 
patients, in non-carriers and in ABCC6 carriers.
Group Baseline Week 1 Week 6 Significance (along time)
Vitamin K metabolites
Serum MK-4 (ng/mL)
Non-carriers 15.5 ± 5.2 25.4 ± 12.4 23.7 ± 32.0 ns
ABCC6 carriers 20.0 ± 14.0 27.1 ± 12.4 23.1 ± 6.9 ns
PXE 28.8 ± 26.9 38.3 ± 32.0 41.6 ± 17.8 ns
Significance (among groups) *§ *§ *§
Serum MK-7 (ng/mL)
Non-carriers 25.1 ± 8.8 22.8 ± 16.9 18.4 ± 7.8 ns
ABCC6 carriers 14.8 ± 11.3 23.4 ± 8.7 22.3 ± 8.0 ns
PXE 12.2 ± 8.7 23.0 ± 9.0 22.3 ± 2.0 ns
Significance (among groups) ns ns ns
Urinary 5C-vitamin K metabolite (mg/g)
Non-carriers 6.86 ± 2.71 7.34 ± 2.82 4.21 ± 1.88 ns
ABCC6 carriers 3.87 ± 3.32 4.53 ± 3.53 3.15 ± 3.12 ns
PXE 3.27 ± 2.61 4.23 ± 4.35 3.63 ± 2.25 ns
Significance (among groups) * * ns
Urinary 7C-vitamin K metabolite (mg/g)
Non-carriers 3.41 ± 1.48 3.98 ± 1.56 2.65 ± 1.22 ns
ABCC6 carriers 1.54 ± 1.16 2.55 ± 1.89 1.64 ± 0.90 ns
PXE 2.21 ± 1.33 2.49 ± 1.59 1.96 ± 1.28 ns
Significance (among groups) ns ns ns
Total urinary vitamin K metabolites (mg/g)
Non-carriers 10.2 ± 4.19 11.3 ± 4.06 6.86 ± 2.89 ns
ABCC6 carriers 5.40 ± 4.45 7.07 ± 5.27 4.79 ± 3.80 ns
PXE 5.48 ± 3.71 6.72 ± 5.71 5.59 ± 3.26 ns
Significance (among groups) ns ns ns
Vitamin K-dependent proteins
Serum GAS6 (ng/mL)
Non-carriers 58.7 ± 7.61 52.8 ± 18.7 41.2 ± 5.4 p < 0.05
ABCC6 carriers 51.9 ± 9.18 46.3 ± 7.1 40.6 ± 7.4 p < 0.05
PXE 47.3 ± 9.14 47.9 ± 11.4 38.9 ± 8.6 p < 0.05
Significance (among groups) ns ns ns
Serum Glu-Osteocalcin (ng/mL)
Non-carriers 7.0 ± 1.5 3.1 ± 1.5 5.9 ± 2.2 p < 0.05
ABCC6 carriers 14.6 ± 8.8 11.5 ± 8.9 13.9 ± 8.8 p < 0.05
PXE 11.7 ± 5.4 7.2 ± 2.6 10.1 ± 4.9 p < 0.05
Significance (among groups) ns ns ns
Serum Gla-Osteocalcin (ng/mL)
Non-carriers 12.4 ± 5.5 18.6 ± 4.9 13.0 ± 6.0 p < 0.05
ABCC6 carriers 13.7 ± 5.9 20.2 ± 8.9 14.2 ± 5.4 p < 0.05
PXE 12.6 ± 8.3 15.9 ± 9.1 14.3 ± 9.6 p < 0.05
Significance (among groups) ns ns ns
PIVKA-II (ng/ml)
Non-carriers 1.35 ± 0.56 1.13 ± 0.48 1.17 ± 0.72 ns
ABCC6 carriers 1.56 ± 0.58 1.29 ± 0.44 1.33 ± 0.41 ns
PXE 1.25 ± 0.38 1.13 ± 0.44 1.11 ± 0.50 ns
Significance (among groups) ns ns ns
Serum Fetuin (ng/mL)
Non-carriers 893 ± 535 843 ± 498 925 ± 646 ns
ABCC6 carriers 959 ± 453 927 ± 364 813 ± 325 ns
PXE 795 ± 146 787 ± 227 834 ± 223 ns
Significance (among groups) ns ns ns
*p < 0.05 ABCC6 carriers or PXE versus non-carriers.
§p < 0.05 ABCC6 carriers versus PXE.
Data shown as mean ± SD.
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To evaluate the effects of phytomenadione administration on 
extra-hepatic tissues, we measured plasma levels of Gas6, a vita-
min K-dependent protein that, differently to the homologous 
anticoagulant protein S (35, 36), is synthesized by fibroblasts, 
endothelium, vascular smooth muscle, and bone marrow cells 
(37, 38), although its role in the calcification process still remains 
on a speculative basis (39). According to our results, plasma 
levels of this protein, at baseline, were similar in all groups and 
progressively decreased with time, without significant differ-
ence between patients and unaffected subjects. Since vitamin 
FIGURE 2 | Ratio of circulating Glu-osteocalcin (Glu-OC) and Gla-osteocalcin 
(Gla-OC) measured by ELISA in pseudoxanthoma elasticum (PXE) patients, in 
heterozygous ABCC6 mutation carriers (ABCC6 carriers) and in non-carriers 
after 1 and 6 weeks post-phytomenadione administration. Data are 
expressed as percentage reduction (means value ± SD) compared to 
baseline (p < 0.05 along time for the three groups).
FIGURE 1 | 5C- and 7C-aglycone urinary vitamin K metabolites were measured by HPLC (mg/g creatinine) in pseudoxanthoma elasticum (PXE) patients,  
in heterozygous ABCC6 mutation carriers (ABCC6 carriers) and non-carriers at baseline (week 0) and after 1 and 6 weeks after parenteral phytomenadione 
administration. Data are expressed as mean values ± SD in upper panels and as percentage of 5C- or 7C-aglycone ratio on total aglycones in lower panels.
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K-dependent carboxylation of Gas6 favors protein binding to 
the Axl tyrosine kinase receptors (40), it could be suggested 
that the decrease in Gas6 levels observed in this study could be 
related to increased binding and consequently to reduced avail-
ability of free Gas6 in serum, further supporting the concept that 
vitamin-K dependent carboxylation per se is not affected in PXE.
To further assess the effects of parental phytomenadione 
administration, we have evaluated the carboxylated (gla) and 
undercarboxylated (glu) forms of OC, a protein involved in the 
remodeling of calcified matrix (14). In agreement with previous 
data (18) baseline glu-OC and gla-OC levels were not modified 
in PXE compared to unaffected subjects. Moreover, results sup-
port the observation that PXE patients similarly to unaffected 
subjects respond to vitamin K administration (10) by increasing 
carboxylated-OC. Since, vitamin K is believed to prevent vascu-
lopathy (41), the hypothesis that prolonged elevation of vitamin 
K-dependent Gla-OC may delay tissue calcification could be 
explored in future studies.
Finally, the observation that fetuin A, a non-vitamin 
K-dependent α-glycoprotein synthesized by hepatocytes, is not 
affected by treatment, is a clear demonstration that changes 
observed after phytomenadione administration are the result of 
the treatment and not of non-specific metabolic interactions, e.g., 
acute phase response.
It has to be taken into account that PXE is a rare disorder. 
A restriction of the present investigation is related to the low 
number of patients enrolled and the resulting limited statistical 
power. Nevertheless, results from this pilot study indicate that, 
in PXE, phytomenadione might be able to positively influence 
the g-carboxylation process, thus indicating a proof of concept 
that vitamin K may actually exert some beneficial effects on 
calcification-related proteins.
CONCLUSION
In conclusion and examining vitamin K-dependent proteins 
and vitamin K metabolites, this pilot study indicates that PXE 
patients demonstrate altered vitamin K metabolism compared 
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to heterozygotes and non-carriers. Despite this, the response to 
parenteral phytomenadione administration is similar in patients 
and in unaffected individuals, suggesting that the physiological 
axis between vitamin K and vitamin K-dependent proteins is 
preserved in PXE. Because vitamin K is known to prevent vascu-
lopathy (41), the elevation of Gla-OC seen in PXE patients after 
phytomenadione administration, may suggest that vitamin K 
treatment, if sustained over time, could contribute to delay tissue 
calcification.
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